公开(公告)号：EP2874998B1

公开(公告)日：2018-09-12

申请号：EP13735285.2

申请日：2013-07-11

申请人： Rhodia Opérations

发明人： BESSON, Bernard ,  METZ, François ,  BUISINE, Olivier

IPC分类号： C07C303/02 ,  C07C303/38 ,  C07C303/44 ,  C07C311/48

CPC分类号： C07C303/40 ,  C07C51/412 ,  C07C303/36 ,  C07C303/38 ,  C07C303/44 ,  C07C315/00 ,  C07C315/04 ,  C07C311/48

公开(公告)号：EP3365330A1

公开(公告)日：2018-08-29

申请号：EP16858474.6

申请日：2016-10-22

申请人： Mangosuthu University Of Technology

发明人： GUMEDE, Njabulo Joyfull

IPC分类号： C07D265/36 ,  A61K31/538 ,  C07D413/12 ,  C07D309/34 ,  C07D405/14 ,  C07D417/12 ,  C07C311/29 ,  C07C237/20 ,  C07D231/56 ,  C07C235/56 ,  C07D405/12 ,  C07D401/14 ,  C07D495/04 ,  C07D249/12 ,  C07D279/16 ,  A61K31/351 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/18 ,  A61K31/167

CPC分类号： C07D413/12 ,  C07C237/22 ,  C07D231/56 ,  C07D265/36 ,  C07D309/34 ,  C07D417/12

摘要： The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compounds have the formula: [Chem. 1] wherein: R is independently selected from the group consisting of optionally substituted arylamide; optionally substituted alkylarylamide; optionally substituted aryl carboxamide; optionally substituted cyanopiperidine; optionally substituted oxopiperidine; optionally substituted N-(pyridin-3-yl); optionally substituted pyridin-3-yl; optionally substituted pyrazole-4-carboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted 1H-pyrrol-2-ylcarboxamide; optionally substituted morpholin carboxamide; optionally substituted 1H-indazol-3-ylcarboxamide; optionally substituted 5-cyanopiperidin-3-ylcarboxamide; optionally substituted quinolin-7-yl; optionally substituted pyrazin-2-ylcarboxamide; optionally substituted 1H-1,3-benzodiazole-6-carboxamide; and optionally substituted 3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-ylcarboxamide; Each R1, R2, R3, R4, R5 is independently selected from the group consisting of H; OH; a halogen atom; OCH3; and NH2; and X is independently selected from the group consisting of O, H and OH. Some of the compounds are claimed per se and the invention also encompasses pharmaceutically acceptable salts, solvates, hydrates, primary metabolites and prodrugs thereof.

公开(公告)号：EP3252035A4

公开(公告)日：2018-08-01

申请号：EP16743678

申请日：2016-01-27

申请人： LG CHEMICAL LTD

发明人： JANG YONG JIN ,  HAN JOONG JIN ,  KIM YOUNGJEA ,  KANG ESDER ,  JUNG SEHEE ,  RYU HYUN WOOG ,  YU YUNAH

IPC分类号： C07C311/48 ,  B01J39/19 ,  C08G65/40 ,  C08J5/22 ,  H01M8/10 ,  H01M8/1018 ,  H01M8/18

CPC分类号： C07C311/48 ,  B01J39/19 ,  C08G65/4018 ,  C08G2650/38 ,  C08G2650/40 ,  C08G2650/50 ,  C08J5/2256 ,  C08J2371/10 ,  H01M8/1004 ,  H01M8/1018 ,  H01M8/18 ,  H01M8/188 ,  H01M2008/1095 ,  Y02E60/528

摘要： The present specification relates to a compound comprising an aromatic ring, a polyelectrolyte membrane comprising the same, a membrane-electrode assembly comprising the polyelectrolyte membrane, a fuel cell comprising the membrane-electrode assembly, and a redox flow battery comprising the polyelectrolyte membrane.

公开(公告)号：EP3342599A1

公开(公告)日：2018-07-04

申请号：EP16846443.6

申请日：2016-09-13

申请人： Sanko Co., Ltd.

发明人： ISHIBASHI Yoshimi ,  KINISHI Ryoichi ,  NAKAGAWA Yoshito

IPC分类号： B41M5/333 ,  C07C275/28 ,  C07C311/42 ,  C07C311/58 ,  C07C335/16 ,  C07C323/59 ,  C07K5/062 ,  C07K5/083

CPC分类号： B41M5/3333 ,  B41M5/327 ,  B41M5/3275 ,  B41M5/3335 ,  B41M5/3375 ,  C07C237/40 ,  C07C275/28 ,  C07C275/42 ,  C07C311/19 ,  C07C311/42 ,  C07C311/51 ,  C07C311/58 ,  C07C323/59 ,  C07C335/16

摘要： A heat-sensitive recording material includes a heat-sensitive recording layer containing a basic dye and a developer and provided on a supporting body, in which the developer is at least one type of an N-substituted amino acid derivative represented by the following General Formula: (R-X) m -Y-(Z) m ... (1) (In Formula (1), R represents an alkyl group or an aryl group which may have a substituent. X is a group bonded to the N-terminus of Y, and represents -OCO-, -SO 2 NHCO-, -NHCO-, -NHCS-, or -SO 2 -. Y represents an amino acid residue or a peptide residue. Z represents a group bonded to the C-terminus of Y and represents an OH group or an OR" group. When Y is an amino acid residue other than a cystine residue or when Y is a peptide residue not having a cystine residue, m = 1, and when Y is a peptide residue having n cystine residues, m = n + 1 and n is 1 or 2.)

公开(公告)号：EP3341357A1

公开(公告)日：2018-07-04

申请号：EP16840923.3

申请日：2016-08-26

申请人： Glenmark Pharmaceuticals S.A.

发明人： DAS, Sanjib ,  GHARAT, Laxmikant Atmaram ,  HARDE, Rajendra Laxman ,  SHELKE, Dnyaneshwar Eknath ,  PARDESHI, Shailesh Ramesh ,  THOMAS, Abraham ,  KHAIRATKAR-JOSHI, Neelima ,  SHAH, Daisy Manish ,  BAJPAI, Malini

IPC分类号： C07C311/16 ,  A61K31/167 ,  A61P35/00

CPC分类号： C07C237/42 ,  A61P11/06 ,  A61P11/08 ,  A61P11/14 ,  A61P17/06 ,  C07B2200/07 ,  C07C2601/02 ,  C07C2601/16

摘要： The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：EP3326229A1

公开(公告)日：2018-05-30

申请号：EP16753948.5

申请日：2016-07-21

申请人： Centre National de la Recherche Scientifique ,  Institut Polytechnique de Grenoble

发明人： IOJOU, Cristina ,  THIAM, Amadou ,  DANYLIV, Olesia ,  MERCIER, Régis ,  SANCHEZ, Jean-Yves

IPC分类号： H01M10/052 ,  C07C309/02 ,  C07C311/00 ,  C07C317/00 ,  H01M10/0565 ,  C07C309/24 ,  C07C311/48 ,  C07C317/10 ,  C07C317/14 ,  C07C321/28 ,  C08L71/02

摘要： The invention relates to a process for preparing ionomers of unipolar cationic conductivity from fluorine-containing ionic monomers, to said ionomers of unipolar cationic conductivity, to their uses, to an electrolytic composition comprising at least one of said ionomers of unipolar cationic conductivity and to an electrochemical device comprising at least one of said ionomers of unipolar cationic conductivity, especially by way of electrolyte.

公开(公告)号：EP3228614A4

公开(公告)日：2018-05-30

申请号：EP15865915

申请日：2015-11-13

申请人： QINGDAO LANFAN ADVANCED MAT CO LTD

发明人： LIU YANG

IPC分类号： C07C311/46 ,  C07C303/40 ,  G03F7/031

CPC分类号： C07C303/40 ,  C07C311/46 ,  G03F7/027

摘要： The invention belongs to the field of chemical synthesis, in particular to a toluenesulfonamide substituted acrylamide derivative which has the advantages that (1) the traditional preparation route is adopted, process parameter requirements are not high, the preparation is simple, and only an appropriate reactor is required to be selected; (2) a yield is high, and the refining yield can reach above 80%; and (3) the derivative serves as a monomer for synthesizing a copolymer with a sulfamide substituent, and the synthesized copolymer can serve as a major or additive adhesive for a lithographic plate to improve performances of the lithographic plate, such as chemical resistance, abrasive resistance and development printability of a forme.

公开(公告)号：EP3319938A1

公开(公告)日：2018-05-16

申请号：EP16824947.2

申请日：2016-07-08

申请人： University of Maryland, Baltimore

发明人： FLETCHER, Steven ,  LANNING, Maryanna ,  CHEN, Lijia

IPC分类号： C07C311/21 ,  A61K31/381

CPC分类号： C07C311/21 ,  A61P35/02 ,  C07C229/64 ,  C07C311/29 ,  C07C311/51 ,  C07C2601/08 ,  C07D215/58 ,  C07D257/02 ,  C07D261/12 ,  C07D309/04

摘要： Compounds that inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.

公开(公告)号：EP3170789B1

公开(公告)日：2018-04-18

申请号：EP16204180.0

申请日：2012-02-24

申请人： NIPPON SODA CO., LTD.

发明人： TSUBOKURA, Shiro ,  AIURA, Yasuyuki ,  SUZUKI, Toru ,  MARUYAMA, Michiaki

IPC分类号： C01B21/093 ,  C07C303/40 ,  C07C311/48 ,  C01B21/092 ,  H01M10/10 ,  H01M10/052 ,  H01M10/0568

CPC分类号： C07C311/48 ,  C01B21/0923 ,  C01B21/093 ,  C07C303/40 ,  H01M10/052 ,  H01M10/0568 ,  Y02E60/122 ,  Y02P70/54

摘要： A compound [II] such as ammonium N,N-di(fluorosulfonyl)imide is obtained by reacting a compound [I] such as N,N-di(chlorosulfonyl)imide and NH 4 F (HF) p . A compound [IV] such as an N,N-di(fluorosulfonyl)imide alkali metal salt is obtained by reacting the obtained compound [II] and an alkali metal compound or the like.

公开(公告)号：EP3303291A1

公开(公告)日：2018-04-11

申请号：EP16726886.1

申请日：2016-06-03

申请人： Lead Pharma Holding B.V. ,  SANOFI

发明人： CALS, Joseph Maria Gerardus Barbara ,  DE KIMPE, Vera ,  NABUURS, Sander Bernardus

IPC分类号： C07D213/75 ,  C07D213/82 ,  C07D215/08 ,  C07D217/02 ,  C07D223/16 ,  C07D231/40 ,  C07D333/36 ,  C07C311/20 ,  C07C317/32 ,  C07D241/04 ,  C07D417/04 ,  C07D261/08 ,  C07D207/06 ,  C07D495/04 ,  C07D209/08

CPC分类号： C07D213/75 ,  C07C311/20 ,  C07C317/44 ,  C07C317/50 ,  C07C2601/02 ,  C07C2601/04 ,  C07D207/06 ,  C07D209/08 ,  C07D211/16 ,  C07D211/26 ,  C07D211/60 ,  C07D213/82 ,  C07D215/08 ,  C07D217/02 ,  C07D223/16 ,  C07D231/40 ,  C07D241/04 ,  C07D261/08 ,  C07D277/46 ,  C07D285/135 ,  C07D295/13 ,  C07D295/192 ,  C07D307/52 ,  C07D333/36 ,  C07D417/04 ,  C07D495/04

摘要： The present invention relates to compounds according to Formula I : or a pharmaceutically acceptable salt thereof wherein the variables have the meanings defined in the claims. The compounds can be used as inhibitors of ROR³ and are useful for the treatment of ROR³ mediated diseases.